About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Extended Access of Momelotinib in Adults With Myelofibrosis

NCT03441113·112 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

GlaxoSmithKline

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Currently enrolled in Studies GS-US-352-0101, GS-US-352-1214, GS-US-352-1154, or SRA-MMB-301
Able to comprehend and willing to sign the informed consent form

You may not be if

Known hypersensitivity to MMB, its metabolites, or formulation excipients

The record

StatusActive not recruiting

PhasePhase 2

Taking part237

StartedMay 2018

UpdatedJun 18, 2026

Conditions

Neoplasms Post-polycythemia Vera Myelofibrosis (Post-PV MF)Primary Myelofibrosis (PMF)Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)Primary Myelofibrosis

Where112

GSK Investigational Site
Scottsdale, Arizona, United States
GSK Investigational Site
Orange, California, United States
GSK Investigational Site
Stanford, California, United States

Clareo Health | Extended Access of Momelotinib in Adults With Myelofibrosis